Weekly Recap | TMO.US -1.13%, most brokers rate it buy
I'm LongbridgeAI, I can summarize articles.Thermo Fisher (TMO) closed the week at $622.18, down 1.13% against the S&P 500’s +0.49% rise, about 1.62 percentage points behind. It was a choppy, top-heavy week: Monday opened with a dip to $615.97 before rebounding, Tuesday printed the week’s high at $647.00, then the stock drifted lower into Friday’s close near the weekly low. Average daily volume of roughly 1.52m shares ran about 20% below the 60-day median.
The Week
Thermo Fisher (TMO) closed the week at $622.18, down 1.13% against the S&P 500’s +0.49% rise, about 1.62 percentage points behind. It was a choppy, top-heavy week: Monday opened with a dip to $615.97 before rebounding, Tuesday printed the week’s high at $647.00, then the stock drifted lower into Friday’s close near the weekly low. Average daily volume of roughly 1.52m shares ran about 20% below the 60-day median.
Key Events
There were no material company announcements this week. The story was thinner, built around insider selling and scattered institutional adjustments. CEO Marc N. Casper disclosed sales across Tuesday and Thursday, totalling just over 10,000 shares worth north of $15m. On the buy side, Solstein Capital, Parallax Volatility, and United Capital all reported new positions, though each was small enough to read as routine bookkeeping rather than a directional signal.
Analyst Ratings
Of 30 covering institutions, 19 rate the stock buy, 3 rate it outperform, 5 hold, 1 underperform, and 2 have no opinion; no one rates it sell. The consensus recommendation is buy, with a consensus target of $631.42, about 1.49% above spot. Targets range from $520 to $750, a wide spread that points to real disagreement on the longer-term upside. TMO ranks first among 53 names in the life sciences tools and services industry.
The Week Ahead
The first week of September brings a run of US manufacturing and labour readings. Tuesday has the S&P Global manufacturing PMI final, ISM manufacturing PMI, and JOLTS job openings; Wednesday adds ADP private payrolls and factory orders. For an interest-rate-sensitive life sciences tools complex, these releases matter: a rates-driven swing in sentiment would likely pull TMO along as a sector heavyweight.
In Short
TMO drifted lower this week without a company-specific catalyst, trailing the market by about 1.6 points. The rating backdrop still reads as constructive, with a buy consensus and a target sitting modestly above spot, but the $230 gap between high and low targets suggests the sell side has not converged on the medium-term case. The next question is whether next week’s manufacturing and jobs data give the sector a cleaner directional cue.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.